Effects of the growth pattern of medulloblastoma on short-term neurological impairments after surgery: results from the prospective multicenter HIT-SIOP PNET 4 study.

CMS CMS = cerebellar mutism syndrome GTR = gross-total resection NTR = near-total resection PFS = progression-free survival STR = subtotal resection cerebellar mutism syndrome growth pattern medulloblastoma neurological sequelae oncology pediatric neurosurgery resection

Journal

Journal of neurosurgery. Pediatrics
ISSN: 1933-0715
Titre abrégé: J Neurosurg Pediatr
Pays: United States
ID NLM: 101463759

Informations de publication

Date de publication:
17 Jan 2020
Historique:
received: 19 06 2019
accepted: 01 11 2019
entrez: 18 1 2020
pubmed: 18 1 2020
medline: 18 1 2020
Statut: aheadofprint

Résumé

Extensive resection of a tumor in the posterior fossa in children is associated with the risk of neurological deficits. The objective of this study was to prospectively evaluate the short-term neurological morbidity in children after medulloblastoma surgery and relate this to the tumor's growth pattern and to the extent of resection. In 160 patients taking part in the HIT-SIOP PNET 4 (Hyperfractionated Versus Conventionally Fractionated Radiotherapy in Standard Risk Medulloblastoma) trial, neurosurgeons prospectively responded to questions concerning the growth pattern of the tumor they had resected. The extent of resection (gross, near, or subtotal) was evaluated using MRI. The patients' neurological status before resection and around 30 days after resection was recorded. Invasive tumor growth, defined as local invasion in the brain or meninges, cranial nerve, or major vessel, was reported in 58% of the patients. After surgery almost 70% of all patients were affected by one or several neurological impairments (e.g., impaired vision, impaired extraocular movements, and ataxia). However, this figure was very similar to the preoperative findings. Invasive tumor growth implied a significantly higher number of impairments after surgery (p = 0.03) and greater deterioration regarding extraocular movements (p = 0.012), facial weakness (p = 0.048), and ataxia in the arms (p = 0.014) and trunk (p = 0.025) compared with noninvasive tumor growth. This deterioration was not dependent on the extent of resection performed. Progression-free survival (PFS) at 5 years was 80% ± 4% and 76% ± 5% for patients with invasive and noninvasive tumor growth, respectively, with no difference in the 5-year PFS for extent of resection. Preoperative neurological impairments and invasive tumor growth were strong predictors of deterioration in short-term neurological outcome after medulloblastoma neurosurgery, whereas the extent of resection was not. Neither tumor invasiveness nor extent of resection influenced PFS. These findings support the continuation of maximal safe resection in medulloblastoma surgery where functional risks are not taken in areas with tumor invasion.

Identifiants

pubmed: 31952041
doi: 10.3171/2019.11.PEDS19349
pii: 2019.11.PEDS19349
doi:
pii:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-9

Subventions

Organisme : Cancer Research UK
ID : 13457
Pays : United Kingdom

Auteurs

Elizabeth Schepke (E)

1Sahlgrenska Cancer Center, Department of Laboratory Medicine, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg.
2Department of Pediatrics, Sahlgrenska University Hospital, Gothenburg.

Magnus Tisell (M)

3Department of Neurosurgery, Sahlgrenska University Hospital and.
4Institute of Neuroscience and Physiology, Department of Neuroscience, Sahlgrenska Academy, University of Gothenburg, Sweden.

Colin Kennedy (C)

5University of Southampton Faculty of Medicine and University Hospital Southampton National Health Service Foundation Trust, Southampton, United Kingdom.

Stephanie Puget (S)

6Département de Neurochirurgie Pédiatrique, Hôpital Necker-Enfants Malades, Université, Paris, France.

Paolo Ferroli (P)

7Department of Neurosurgery, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.

Mathilde Chevignard (M)

8Rehabilitation Department for Children with Acquired Neurological Injury, Saint Maurice Hospitals, Saint Maurice.
9Laboratoire d'Imagerie Biomédicale and.
10GRC 24 HaMCRe, Sorbonne Université, Paris.

François Doz (F)

11SIREDO Cancer Center (Care, Innovation & Research, in Childhood, Adolescent and Young-Adult Oncology), Institut Curie Paris.
12Department of Pediatrics, University Paris Descartes, Paris, France.

Barry Pizer (B)

13Department of Oncology, Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom.

Stefan Rutkowski (S)

14Department of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Maura Massimino (M)

15Fondazione Istituto di Ricovero e Cura a Carattere Scientifico IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Aurora Navajas (A)

16BioCruces Health Research Institute, Bilbao, Spain.

Edward Schwalbe (E)

17Wolfson Childhood Cancer Research Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle-upon-Tyne.
18Department of Applied Sciences, Northumbria University, Newcastle-upon-Tyne, United Kingdom.

Debbie Hicks (D)

17Wolfson Childhood Cancer Research Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle-upon-Tyne.

Steven C Clifford (SC)

17Wolfson Childhood Cancer Research Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle-upon-Tyne.

Torsten Pietsch (T)

19Institute of Neuropathology, DGNN Brain Tumour Reference Center, University of Bonn, Germany; and.

Birgitta Lannering (B)

20Department of Pediatrics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Germany.

Classifications MeSH